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Lymphomatoid papulosis (LyP) is a disorder described by
Macaulay1 in 1968 as a continuous self-healing, papular
eruption, clinically benign, and histologically malignant.
The disorder is characterized by erythematous papules
and nodules that progress to form vesicular, crusted, or
hemorrhagic lesions and then undergo spontaneous heal-
ing with scarring. Lesions usually occur over the trunk
and limbs. LyP is usually a benign cutaneous disease with
alarming histopathologic features; previously believed to
be an inflammatory process, it is now included among the
cutaneous T-cell lymphomas in the current European
Organization for Research and Treatment of Cancer and
World Health Organization classifications.2
Histopathologically, three types can be distinguished:
type A exhibits wedge-shaped lymphocytic infiltrates with
abundant Reed-Sternberg-like, CD30 (Ki-1) positive cells
mixed with neutrophils and eosinophils; type B shows
lymphocytes with smaller, hyperchromatic, cerebriform
nuclei predominating and fewer or absent CD30 staining
but with marked epidermal involvement; type C displays
a monotonous population of CD30-positive cells.
We describe a case of human cytomegalovirus (HCMV)
associated ulcerative proctitis diagnosed with LyP type B.
A 38-year-old man with a three-month history of rectal
bleeding was referred as an outpatient to an inflammatory
bowel disease referral center in June 2008. One month
before, in May 2008, he underwent a proctoscopy that
showed rectal ulcers 2 cm wide. He also underwent a
biopsy, which revealed a histological description of ulcera-
tive proctitis with evidence of large endothelial cells con-
taining a basophilic intranuclear inclusion (8–10 lm)
eccentrically placed with positivity for HCMV on immuno-
histochemical assay. The immunocytochemical search for
HCMV antigenemia pp65 in peripheral leukocytes was
also positive.
The other laboratory studies were normal, and his med-
ical history was unremarkable, specifically without any
complaint that could be related to bowel disease or
immunosuppressive state. The patient had not received
any immunomodulant treatment before the referral.
At about the same time, the patient reported the
appearance of erythematous papules over the trunk, some
of which evolved into crusted lesions. A skin biopsy
showed a diagnosis compatible with type B (lymphocytic
type) LyP (Figs. 1 and 2). The patient was treated
successfully with topical mesalazine for the ulcerative
proctitis and with psoralen–ultraviolet A with gradual
improvement and disappearance of the eruptions after
eight weeks. No antiviral therapy was dispensed for
HCMV infection due to the rapid clinical improvement of838
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the patient. In August 2008, the patient underwent total
colonoscopy that confirmed only rectal involvement with
no extension of disease and with initial recovery of ulcers
and histological HCMV disappearance.
The patient visited the hospital as an outpatient every
six months. In July 2010, the patient was in stable clinical
remission with topical mesalazine treatment with no other
cutaneous manifestations. As a curative therapy is not
available for LyP and none of the available treatment
modalities affect the natural course of the disease, the
short-term benefits of active treatment should be balanced
carefully against the potential side effects. Low-dose oral
methotrexate (5–20 mg/week) is the most effective therapy
to suppress the development of new skin lesions.
Beneficial effects of psoralen–ultraviolet A and topical che-
motherapy have been reported. However, after discontinu-
ation of treatment, the disease generally relapses within
weeks or months. Therefore, in patients with relatively
few and non-scarring lesions, long-term follow-up without
active treatment should be considered.3 In 10–20% of
patients, it is preceded by, concurrent with, or transforms
into malignant lymphoma, most often anaplastic large cell
(CD30-positive) lymphoma, mycosis fungoides, Hodgkin’s
disease, or non-Hodgkin’s lymphoma of the lymph nodes.
No differences in the overall clinical course have been
linked to these histological subsets.4 To our knowledge,
there are no reports concerning the association between
HCMV and LyP, particularly in patients with inflamma-
tory bowel disease. Several studies have suggested a role
for herpesvirus infection in super-antigenic activation of T
lymphocytes, mainly in other variants of cutaneous T-cell
lymphomas such as mycosis fungoides and Sézary syn-
drome. Two reports show that latent HCMV infection
may play a role in the susceptibility of mycosis fungoides
in predisposed subjects by inducing T-cell proliferation
and resistance to apoptosis; more than 97% of patients
with any at all stages of cutaneous T-cell lymphoma have
evidence for previous infection with human HCMV.5,6
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Figure 2 Dense infiltrate in the dermis with CD30+ large
atypical lymphocytes mixed with small CD30) lymphocytes.
CD30+ immunostaining, · 40
Figure 1 Diffuse dermal–hypodermal infiltrate (consisting
of lymphocytes, eosinophils, and histiocytes) with atypical
lymphoid cells. Hematoxylin and eosin immunostaining ·20
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